中国医院用药评价与分析2017，Vol.17Issue(6)：735-737,741,4.DOI:10.14009/j.issn.1672-2124.2017.06.005
切除修复交叉互补基因1的表达与食管癌临床病理特征和术后含铂类药物辅助化疗疗效的关系
Correlation between Erccl Expression and Clinicopathological Characters and Efficacy of Postoperative Platinum-based Adjuvant Chemotherapy in Esophageal Cancer
摘要
Abstract
OBJECTIVE:To probe into the correlation between ERCCl expression and clinicopathological characters and efficacy of postoperative platinum-based adjuvant chemotherapy in esophageal cancer.METHODS:115 patients with esophageal cancer accepting operation in Shanxi Tumor Hospital from Jan.1st 2013 to Jun.30th 2015 were selected to conduct the ERCCl expression detection,correlation of ERCCl expression and clinicopathological characters were analyzed.RESULTS:The positive expression of ERCCl was 54.8％(63/115).The 1-year recurrence rate of positive expression of ERCCl patients with postoperative platinum-based adjuvant chemotherapy was 17.1％(6/35),1-year survival rate was 82.6％(29/35).And 1-year recurrence rate of negative expression of ERCCl patients with postoperative platinum-based adjuvant chemotherapy was 11.1％(3/27),1-year survival rate was 88.9％(24/27).CONCLUSIONS:There are no correlation between ERCCl expression and patients gender,age,location,length of tumor,degree of tumor differentiation,pathological type,lympho nodemetastasis and international TNM staging system.The 1-year recurrence rate of positive expression of ERCCl patients with postoperative platinum-based adjuvant chemotherapy was higher than that of ERCC1-negative patients.Therefore,patients with ERCC1-negative esophageal cancers may benefit from platinum-based adjuvant chemotherapy.关键词
食管癌/切除修复交叉互补基因1/化疗Key words
Esophageal cancer/ERCC1/Chemotherapy分类
医药卫生引用本文复制引用
张宁刚,李秀秀,宋雪峰,王育生..切除修复交叉互补基因1的表达与食管癌临床病理特征和术后含铂类药物辅助化疗疗效的关系[J].中国医院用药评价与分析,2017,17(6):735-737,741,4.基金项目
山西省科技攻关项目(No.20140313011-11) （No.20140313011-11）
